-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CSL Behring announced today that the European Medicines Agency (EMA) has approved a request for accelerated evaluation of the Marketing Authorization Application (MAA) for the hemophilia B gene therapy etranacogene dezaparvovec (EtranaDez)
Previously, etranacogene dezaparvovec has been granted Breakthrough Drug Designation (BTD) by the US FDA and Priority Drug Designation (PRIME) by the EMA
Recently, Jet Behring announced positive results from the pivotal Phase 3 HOPE-B trial
The study further showed that etranacogene dezaparvovec was well tolerated in the 53 patients involved in the 18-month follow-up, with more than 80% of adverse events considered mild
This article comes from Bio Valley, for more information, please download the Bio Valley APP (http://